Abstract:ABSTRACT Chronic hepatitis B virus (HBV) infections affect over 250 million people worldwide, and over 800,000 are expected to die yearly from complications including cirrhosis and primary hepatocellular carcinoma. While clinically available nucleoside analog-based antiviral therapies inhibit virus production, they cannot cure infections due to the persistence of covalently closed circular (cccDNA) in the nuclei of infected hepatocytes. Hence, the goals of future curative antiviral therapies for chronic hepatitis B are to either eliminate or permanently silence transcription from cccDNA. Novel antiviral approaches building on a better understanding of the mechanisms underlying transcriptional regulation and the stability of HBV cccDNA will be necessary to accomplish such goals. To advance our understanding of cccDNA biology, we have employed a CRISPR/Cas9-based system to produce extrachromosomal circular (ec) DNA from plasmid DNA integrated into the host genome originally developed by Moller et al. [Nucleic Acid Research 46:(22) e131, 2018]. We modified the enhanced green fluorescent protein (EGFP) reporter system to include portions of the HBV genome encoding wild-type and inactive hepatitis B virus X (HBx) proteins on ecDNA to mimic cccDNA. We demonstrated that expression of EGFP is inhibited by the SMC5/6 complex, as is cccDNA, and that HBx expression can reverse transcriptional silencing of ecDNA. Moreover, we demonstrated that ecDNA is lost during cell division. The system described in this report permits investigations on ecDNA and enables large-scale screening of compound libraries for small molecules targeting host factors involved in ecDNA and, by inference, cccDNA transcription, maintenance, and loss during cell division. IMPORTANCE Hepatitis B virus cccDNA is the key target for the necessary development of antiviral therapies aimed at curing chronic hepatitis B. The CRISPR-based system to produce covalently closed circular (cccDNA)-like extrachromosomal DNAs described in this report enables large-scale screens of chemical libraries to identify drug candidates with the potential to permanently inactivate cccDNA. Moreover, this approach permits investigations on unresolved problems as described in this report concerning cccDNA biology including mechanisms of SMC5/6-dependent transcriptional silencing and the contributions of the SMC5/6 complex to cccDNA stability in resting and dividing hepatocytes.

HBV Covalently Closed Circular DNA Targeting by Plant-Derived Chemical Agent: Exploring the Potential of Coumarins

Advances in drugs and biotechnology targeting hepatitis B virus cccDNA

Detection of HBV Covalently Closed Circular DNA

Furanocoumarins promote proteasomal degradation of viral HBx protein and down-regulate cccDNA transcription and replication of hepatitis B virus

New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation

HBV life cycle and novel drug targets

Mapping the Interactions of HBV cccDNA with Host Factors

Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics

[A Short Half-Life of Cccdna Offer or Ignite Hope for Hepatitis B Cure under Nucleos(t)ide Analogues Treatment].

A CRISPR-based system to investigate HBV cccDNA biology

A61 TARGETING A GUANINE QUADRUPLEX IN THE HEPATITIS B VIRUS COVALENTLY CLOSED CIRCULAR DNA GENOME USING SINGLE DOMAIN ANTIBODIES

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B

Novel therapeutic strategies for chronic hepatitis B

Epigenetic regulation and its therapeutic potential in hepatitis B virus covalently closed circular DNA

Pharmacological perspectives and molecular mechanisms of coumarin derivatives against virus disease

Coumarin: An emerging antiviral agent

An Insight into Hepatitis C Virus: In Search of Promising Drug Targets

Novel mechanistic insights – A brand new Era for anti-HBV drugs

Novel Approaches Towards Conquering Hepatitis B Virus Infection

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Classifying Hepatitis B Therapies with Insights from Covalently Closed Circular DNA Dynamics